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VaccinationBackground: In South Africa, influenza vaccination is recommended to all diabetics. However, vaccination
coverage among diabetics remains low. Therefore, this study aimed to explore the knowledge, attitudes,
andpractices amongpeoplewithdiabetes inPretoria regarding seasonal influenzaand influenzavaccination.
Method: A cross-sectional survey was conducted among type 1 and 2 diabetes mellitus patients who
attended diabetic clinics in two major tertiary hospitals in Pretoria, South Africa from October to
December 2015. The pilot-tested questionnaire consists of 32 quantitative questions that covered seasonal
influenza and influenza vaccination in terms of the patient’s demographics, medical history and knowledge,
attitudes and practices.
Results: A total of 292 completed questionnaires were received with a response rate of 70.0%. Of these, 162
participants (55.5%) believed that influenza is the same as common cold.While 96 (32.9%) participants were
aware that theywereathigher riskof complicationsof influenza,only86 (29.5%)participantsconsideredvac-
cination asaneffectivemeans inpreventing serious influenza-relatedcomplication. Even though167 (57.2%)
participants had heard of the vaccine to prevent influenza, only 84 (28.8%) participants were previously vac-
cinated. Multivariate analysis shows that participants with good attitude score for influenza vaccination
were 18.4 times more likely to be vaccinated compared with those with poor attitude score (OR =18.4,
95%CI. 5.28–64.10, p = .001). Among those previously vaccinated, advice from their doctors (82/84, 97.6%)
was the main factor encouraging vaccination. Top reasons given by participants who had never been vacci-
nated before (208/292, 71.2%) include use of alternative protection (107/208, 51.4%) and that vaccination is
not necessary because flu is just a minor illness (93/208, 44.7%).
Conclusion: Uptake of seasonal vaccination among diabetics in Pretoria is low. Level of knowledge and per-
ceptionare themainbarriers to vaccination.Health care provider’s advicemaybean important key predictor
of previous influenza vaccination and they should continue to educate and encourage all diabetics to get vac-
cinated for influenza at least once yearly.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza, a mild to severe respiratory infection, is one of the
most common vaccine-preventable diseases affecting people of
all age groups worldwide. Annually it is estimated that it attacks
5–10% of adults and 20–30% of children globally and causes signif-
icant levels of illness, hospitalisation and death [1]. Worldwide,
these annual influenza epidemics are estimated to result in about
3–5 million cases of severe illness, and about 250,000–500,000deaths [2]. Severe morbidity and mortality during typical influenza
seasons occurs among persons aged 65 years and those who have
chronic medical conditions like diabetes mellitus [3]. Diabetes
mellitus (DM) is one of the leading causes of death worldwide,
accounting for an estimate of 1.5 million deaths worldwide in
2015 [4]. DM is the 3rd leading cause of death in South Africa with
a prevalence of 7% among the adult population (20–79 yrs) in 2014
and about 2.28 million cases of diabetes were reported in 2015
[5,6]. Studies have shown that people with diabetes are 3–6 times
more likely to be hospitalised with influenza complications than
people without diabetes and death rates among diabetics increase
5–15 percent during influenza epidemics [7,8].
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months of winter (May to August), sometimes continuing for a
short period into September [9]. Seasonal influenza commonly
known as flu is associated with considerable economic burden
and still a challenging field for the public health system [10,11].
During influenza season it is estimated that influenza-like illness
is responsible for 45% of workdays lost and for 49% of low produc-
tivity days among working adults aged 50–64 years in the United
States [12]. It is estimated that between 6734 and 11619 individ-
uals die of seasonal influenza-associated illness in South Africa
each year [13,14].
Vaccination has been found to be the most effective way to pre-
vent infection and severe outcomes caused by influenza viruses.
[15]. Although patients with diabetes may have abnormalities in
immune function [16], they have appropriate humoral immune
responses to vaccination [17,18] and immunization against influ-
enza has been associatedwith substantial health and economic ben-
efits with previous studies showing reduction of hospital admission
by 79% during influenza epidemics among diabetics [19,20].
Therefore, the United States Advisory Committee on Immuniza-
tion Practices (ACIP) and the International Diabetes Federation
(IDF), in view of the efficacy of influenza vaccination, recommend
influenza vaccination of all diabetics across all ages [21,22]. Influ-
enza vaccine coverage continues to vary across different geograph-
ical locations, and vaccine supply still remains low in Africa.
Generally, the rate of influenza vaccination is universally low
[23,24] and with an estimated coverage rate of about 9% in South
Africa in 2005 among adult (17–64 years) and elderly (65 years)
age group in the urban setting [25]. Even though South Africa is
one of the six countries in Africa recommending the use of influ-
enza vaccination in their national immunization schedule, the
influenza vaccination uptake is low [23,26,27]. Despite the yearly
influenza vaccination campaign initiated in 2010 by the South Afri-
can National Department of Health in collaboration with National
Institute for Communicable Diseases (NICD) to increase vaccina-
tion awareness among high risk groups which include diabetics
[28,29], there is no recent published study in South Africa assessing
the knowledge, attitudes, and practices (KAPs) of diabetics regard-
ing seasonal influenza and influenza vaccination; and evaluating
vaccine uptake among this high risk group.
The aim of this study was therefore to assess the knowledge,
attitudes and practices among diabetic patients in Pretoria regard-
ing seasonal influenza and influenza vaccination. It also aimed to
assess the uptake of seasonal influenza vaccine among diabetics
and identify factors influencing such practices.2. Methods
The study is a cross sectional survey that took place at two gov-
ernment tertiary hospitals (Dr. George Mukhari and Steve Biko hos-
pitals) in Pretoria, South Africa. These hospitals have been
purposively selected because they serve as referral centres for most
hospitals in Pretoria and have a large base of patients in the endo-
crine clinicswhere the diabetic patients are seen. All type 1 and type
2 DM patients above 18 years irrespective of gender and race were
eligible for the study with the exclusion of diabetic patients on
admission and at the emergency department of the hospital. Also
patients attending clinic more than once during the period of the
study were not allowed to participate more than once in the study.
The study was approved by the Research Ethics Committee of
Stellenbosch University, and from the appropriate research ethics
body of both hospitals prior to study initiation. The survey was
conducted at the end of the influenza season among all eligible dia-
betes mellitus patients who attended the weekly endocrine or dia-
betic clinic of both hospitals between October and December 2015;following pilot interviews conducted in September 2015. Primary
data were collected using interviewer administered structured
questionnaire (Appendix A) after obtaining written informed con-
sent from all participants. Informed consent was witnessed in situ-
ations where participants were illiterate. All eligible patients who
attended the clinics during the proposed study period were
selected and approached to participate in the study. The question-
naires were administered by the study physician and assisted by a
trained nurse with background experience in diabetic care during
normal routine consultation at the clinics with prior explanation
and information given to all participants. However, no further clar-
ification was provided in order to standardise the procedure of fill-
ing out the questionnaire. Both the study physician and the nurse
are not regular health care giver of these patients and have not pre-
viously encountered any of these patients.
A minimum sample size of at least 97 diabetics was calculated
based on an estimated 50% uptake rate of the influenza vaccina-
tion, with allowable error of 10% (total width of the confidence
interval) and 95% level of confidence. We enrolled 292 participants
in order to increase the precision of our estimates and allow for
missing data.
The cutoff scores for knowledge and attitude questions were
established a priori. Knowledge was scored and graded as good
(score 65%, from the questions on knowledge) or poor (score
<65%) based on the number of knowledge questions answered cor-
rectly. This scoring system is applicable to knowledge score for sea-
sonal influenza (14 correct answers out of 22), influenza vaccine
(13 correct answers out of 20) and combined knowledge score
for both seasonal influenza and vaccination (27 correct answers
out of 42). Also, attitude was categorised as positive (4 positive
responses out of 7 questions) or negative (3 negative responses
out of 7) based on the responses from the attitude questions.
For the descriptive analysis, Chi-square and Fisher’s exact tests
were used to compare the categorical outcomes. Logistic regression
models were used to explore the factors associated with previous
vaccination. Univariate analysis was performed using all relevant
independent variables as covariates one at a time. For the multi-
variate analysis, forward stepwise modelling was used. Indepen-
dent variables were selected starting from the most significant
variable identified in the univariate analysis and the likelihood
ratio test was used to determine whether the inclusion of a covari-
ate significantly improved the model’s fit. All statistical analyses
were performed using STATA version 12.0 (StataCorp. Texas) and
all tests were conducted at the 5% level of significance.3. Results
A total number of 292 patients participated in the study with a
response rate of 70.0% (292/415). The mean age of participants was
49 years (SD = 14.25) and most of the participants (182/292, 61.6%)
were above 45 years with majority (241/292, 82.5%) being blacks
(Table 1).
When asked about of flu, majority believed flu is a preventable
illness (231/292, (79.1%) and caused by virus (235/292, 80.5%)
while 162 participants (55.5%) still believed that it is the same as
common cold.
Regarding the major symptoms of influenza, the most frequent
choices were running nose (288/292, 98.6%), sneezing (285/292,
97.6%), headache (267/292, 91.4%), sore throat (265/292, 90.8%)
and cough (264/292, 90.4) (Table 2). Flu was not seen to be more
serious among diabetics by majority of the participants (180/292,
61.6%) as only 96 participants (32.9%) believed that flu can cause
serious complications among diabetics (Table 2).
Only 24% (70/292) of patients had previously been admitted in
the hospital for flu related illness.
Table 1
Demographic characteristics of participants (n = 292).
Characteristics Number Percentage
Gender
Male 141 48.29
Female 151 51.71
Age category
>15–25 19 6.50
>25–35 41 14.04
>35–45 52 17.81
>45–55 68 23.29
>55–65 81 27.74
>65–75 24 8.22
>75–85 7 2.40
Marital status
Single 102 34.93
Married 132 45.21
Separated 5 1.71
Divorced 25 8.56
Widow 28 9.59
Level of education
Primary 107 36.64
Secondary 156 53.42
Tertiary 29 9.93
Race
Black 241 82.53
White 18 6.16
Coloured 22 7.53
Indian 11 3.77
Duration of being diabetic
0–5 yrs 60 20.55
6-M 10 yrs 100 34.25
11–15 yrs 69 23.63
More than 15 yrs 63 21.58
Table 2
Perception of seasonal influenza, common symptoms and complications associated
with influenza among participants (n = 292).
Participants Number (%)
Seasonal influenza
Flu is caused by a virus 235 (80.5)
Flu can spread from one person to the other 250 (85.6)
Flu can be prevented 231 (79.1)
Flu is the same as common cold 129 (44.2)
Flu occurs at certain period of the year 232 (79.5)
Flu symptoms are worse among diabetics 112 (38.4)
Flu causes serious complication among diabetics 96 (32.9)
Symptoms
Running Nose 288 (98.6)
Sneezing 285 (97.6)
Headache 267 (91.4)
Sore throat 265 (90.8)
Cough 264 (90.4)
Vomiting 131 (44.8)
Fatigue 100 (34.6)
Muscle ache 97 (33.2)
Fever 67 (23.0)
Diarrhoea 60 (20.6)
Abdominal pain 42 (14.4)
Complications
Poor blood sugar control 73 (25.0)
High risk of hospitalisation 61 (20.0)
Pneumonia 26 (8.9)
Hypertension 2 (0.7)
Gangrene 2 (0.7)
Chest pain 1 (0.3)
Tuberculosis 1 (0.3)
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vaccine to prevent flu, only 50.3% (84/167) of participants had ever
been vaccinated in the past for flu. Majority (147/167, 88%) indi-
cated that the vaccine is safe, and 83.8% (140/167) believed it
works to prevent flu, although 38.3% (64/167) of participantswho believed in the efficacy of the vaccine indicated that one can
still develop flu despite being vaccinated. Few participants
(34/167, 20.1%) reported knowing side effects of the vaccine,
among which headache (100%), nausea (85.3%), soreness/swelling
at injection site (64.7%), and muscle ache (52.9%), were the most
frequently reported.
When previously ever vaccinated patients were asked how long
the vaccine can protect against having flu, majority (152/167,
91.6%) indicated that it can only protect for one flu season and that
themost appropriate time to take the vaccine is before the flu season
starts (155/167, 92.8%). 51.5% (86/167) of participants believe that
the vaccine can prevent serious complications among diabetics,
and previously vaccinated participants have significant better per-
ception of influenza vaccine preventing serious complication among
diabetics (54/84, 64.3%) (Table 3). Majority of participants have pos-
itive attitude (200/292, 68.5%) towards seasonal flu vaccination,
even though only 37.7% (110/292) and 11.3% (33/292) has good
knowledge about seasonal flu and vaccine respectively (Tables 4–6).
Regarding the general attitude of entire participants to influ-
enza vaccination, most participants agreed that annual influenza
vaccination is important among diabetics (189/292, 64.7%) and
65.4% (191/292) would recommend it for all diabetics. Recommen-
dation for vaccination of all diabetics was more observed among
participants with better perception that flu can be prevented.
Majority (237/292, 81.2%) also indicated that if there was an effec-
tive vaccine to prevent flu, they would take it (Table 7). When
asked about their previous influenza vaccination practice, 28.8%
(84/292) had previously been vaccinated at one point in time of
their life. Majority of them (68/84, 81%) received the vaccine
yearly, 11% (9/84) have it every 2 years, and only 5% (4/84) have
had the vaccination once. Factors that influenced decision for vac-
cination included advice from the doctor that it is important
(82/84, 97.6%), being told by fellow patients that it is effective
(46/84, 54.7%) and the vaccine made available free of charge
(33/84, 39.3%) (Table 8).
Majority of participants had never received influenza vaccina-
tion before (208/292, 71.2%) and the main reasons given by them
included use of alternative protection (51.4%), vaccination is not
necessary because flu is just a minor illness (44.7%), and vaccine
is expensive (31.3%) (Table 9).
From the multiple logistic regression analysis, age, duration of
diabetes of 6–10 years, attitude score and combined knowledge
of seasonal influenza and influenza vaccination score were signifi-
cantly and independently associated with previous influenza vacci-
nation after adjusting for the other variables in the model (Table 9).
Participants with diabetes duration of 6–10 years were 4.3 times
more likely to be vaccinated compared to participants with dia-
betes of 5 years or less duration (OR = 4.3, 95%CI. 1.70–10.98 p =
.002). Participants with good attitude score for influenza vaccina-
tion were 18.4 times more likely to be vaccinated compared with
those with poor attitude score (OR = 18.4, 95%CI. 5.28–64.10, p =
.001), while participants with good combined knowledge of sea-
sonal influenza and influenza vaccination score were 3.8 times
more likely to be vaccinated compared with those with poor com-
bined knowledge score (OR = 3.78, 95%CI. 1.81–7.87, p < .001).
When compared to the age group of <25 years, participants in
the >35–55 years age group were 84% less likely to be vaccinated
(OR = .16, 95%CI. 0.04–0.65, p < .011), while those >55 years were
96% less like to get vaccinated (OR = .08, 95%CI. 0.02–0.36, p =
.001) (Table 10).4. Discussion
From this study, the knowledge of vaccine is extremely low as
only 11% of participants who have heard of the influenza vaccine
Table 3
Knowledge and attitudes pertaining to influenza vaccination based on previous influenza vaccination history.
No. (%) p-valuea
Total (n = 292) Vaccinated Not vaccinated
Believes influenza vaccine is safe 147(50.3) 78(53.06) 69(46.94) 0.10
Believes influenza vaccine work to prevent flu 140(47.9) 74(52.86) 66(47.14) 0.09
Believes influenza vaccine has side effect 34(11.6) 21(61.76) 13(38.24) 0.30
Believes influenza vaccine can protect for only One flu season 152(52.1) 77(50.66) 75(49.34) 0.55
Believes Influenza vaccine can prevent serious complication among diabetics 86(29.5) 54(62.69) 32(37.21) 0.005
Believes Influenza vaccination is important among diabetics and should be taken yearly 189(64.7) 77(40.74) 112(59.26) 0.00
Disagrees that influenza vaccine has serious side effect and therefore should not be taken 141(48.3) 53(37.54) 88(62.41) 0.001
Would take influenza vaccine to prevent if effective 237(81.2) 83(35.02) 154(64.98) 0.00
Would recommend influenza vaccine to all diabetics 191(65.4) 77(40.31) 114(59.69) 0.00
a Comparing participants who had been previously vaccinated with those who had never been vaccinated.
Table 4
Seasonal flu knowledge scores of participants (n = 292).
Seasonal flu knowledge score Participants (%)
Good seasonal flu knowledge 110 (37.7)
Poor seasonal flu knowledge 182 (62.3)
Table 5
Vaccine knowledge scores of participants (n = 292).
Flu vaccine knowledge score Participants (%)
Good vaccine knowledge 33 (11.3)
Poor vaccine knowledge 259 (88.7)
Table 6
Attitude scores of participants (n = 292).
Attitude score Participants (%)
Positive attitude 200 (68.5)
Negative attitude 92 (31.5)
Table 8
Factors influencing previous influenza vaccination among participants (n = 84).
Factors Participants (%)
Advice from the doctor that it is important 82 (97.6)
Being told by fellow patients that it is effective 46 (54.7)
Vaccine made available free of charge 33 (39.3)
Advice from the pharmacist 1 (1.2)
Table 9
Reasons given by the participants for not receiving influenza vaccination previously
(n = 208).
Reason Participants (%)
I have alternative protection 107 (51.4)
It is not necessary because flu is just a minor illness 93 (44.7)
It is expensive 65 (31.3)
People who had the vaccine still eventually had the flu 30 (14.4)
Fear of needles and injection 27 (13.0)
The vaccine is not effective 21 (10.1)
It has serious side effect 12 (5.8)
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have heard about the influenza vaccine before believe in its effec-
tiveness and safety, only half of them has ever been vaccinated
before. Participants are well aware of the common symptoms of
seasonal influenza as majority believed that running nose, sneez-
ing, headache, sore throat and cough are associated with influenza
related illness [30]. People with diabetes (type 1 and 2), even when
well-managed, are at high risk of serious flu complications like
pneumonia, bronchitis, sinus infections, ear infections and poor
sugar control [7,30]. In this study however, flu is not seen to be
worse among diabetics and complications of influenza aren’t per-
ceived as any different among them.
The perception of risk appears to be a significant factor for pre-
vious vaccination as participants who were previously vaccinated
had better perception of influenza vaccine preventing serious com-
plication among them (54/84, 64.3%, p = .005). This is a similar
finding in previous studies that has shown that risk perception
plays a significant role in influenza vaccination [31,32]. Recom-Table 7
Attitudes of participants regarding seasonal influenza vaccination (n = 292).
Influenza vaccination is important among diabetics and should be taken yearly
Influenza vaccine prevent serious complication among diabetics
Influenza vaccine has serious side effect and therefore should not be taken
All diabetics should receive influenza vaccine
Flu is a mild illness and therefore vaccination is not necessary
I don’t need the flu vaccine because I have life immunity against flu
If there is an effective vaccine to prevent flu, I will take itmendation for vaccination for all diabetics is also more among
those with better perception that flu can be prevented (161/191,
84.3%, p = .000), and majority of participants (81.2%) indicated
their willingness for flu vaccination if there is an effective vaccine.
Therefore there is need to develop awareness of the peculiarities of
presentation of influenza in diabetics and the importance of influ-
enza vaccination in order to reduce morbidity and mortality in this
high risk group. Vaccination among this high risk group has been
found to reduce outpatient visits, hospitalisation from pneumonia
and even death [7,20]. Its effectiveness however depends on char-
acteristics of those being vaccinated (age and health), whether
there is a good match between the circulating viruses and the
viruses contained in the vaccine, and on influenza types and sub-
types [28,33]. The influenza season of 2015 in South Africa was
predominately influenza A (H1N1) pdm09 with additional co-
circulation of influenza A (H3N2) and influenza B [28,34]. Accord-
ing to the National Institute for Communicable Diseases (NICD) in
collaboration with the South African National Department ofNumber (%)
Agree Disagree Don’t Know
189(64.7) 20(6.9) 83(28.4)
98(33.6) 92(31.5) 100(34.6)
24(7.9) 141(48.3) 128(43.8)
191(65.4) 28(9.6) 73(25)
20(6.9) 184(63.0) 88(30.1)
13(4.5) 183(62.7) 96(32.9)
237(81.2) 6(2.1) 49(16.8)
Table 10
Factors potentially influencing previous vaccination among people with diabetes.
Previously ever vaccinated
Adjusted
0R
95%CI p-value
Age group (<25 years)
>25–35 years 0.43 (0 0.11–1.61) 0.209
>35–45 years 0.16 (0.04–0.65) 0.011
>45–55 years 0.16 (0.04–0.65) 0.010
>55 years 0.08 (0.02–0.36) 0.001
Duration of diabetes (<6 years)
6–10 years 4.32 (1.70–10.98) 0.002
11–15 years 2.03 (0.63–6.57) 0.236
>15 years 2.50 (0.71–8.82) 0.155
Attitude score (good versus poor) 18.40 (5.28–64.10) 0.001
Combined flu and vaccine knowledge
score (good versus poor)
3.78 (1.81–7.87) <0.001
Relevant independent variables included in the logistic regression includes age
group categories, duration of diabetes, attitude score, and combined flu and vaccine
knowledge.
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targeted to receive the influenza vaccine yearly [28,35]. Influenza
vaccine is recommended to be given sufficiently early before win-
ter to provide protection for the winter season because protective
antibody response generally takes about 2 weeks to develop fol-
lowing vaccination [28,33].
In this study, influenza vaccine uptake among diabetics is low as
only 28.8% of participants have previously been ever vaccinated
against influenza. This is similar to the findings in a study done in
2007 at Singapore where the vaccine uptake among diabetics was
30.6% [36]. Influenza vaccination coverage still remains low in Afri-
can and South Asian countries, and this may be largely attributed to
the low vaccine supply and availability in these regions [37]. Influ-
enza vaccination is included in the South African national immu-
nization guideline and made available in the country through the
public and private sector [23,27,28]. Unlike South Africa, influenza
vaccine is not included in the Singapore national immunization pol-
icy and largelymade available through the private sector [38]. How-
ever, the uptake of influenza vaccine among diabetics in Singapore
has been largely attributed to increasedpublic awareness of the vac-
cine following the SARS epidemic in 2003, indicating that it might
have induced the public to seek vaccination against influenza [39].
Uptake is higher among participants with better perception of
the vaccine being able to prevent complication among diabetics
and its yearly importance. Therefore, better knowledge of both
the vaccine and flu influence decision to get vaccinated. There is
no recent published study in South Africa to evaluate the influenza
vaccine uptake rate among diabetics. However a study done in
2004 shows the vaccination rate among the high risk group to be
16.9% [24]. An uptake rate of 28.8% in this study could be a reflec-
tion of the impact of the increasing awareness about seasonal flu in
South Africa.
Major predictors of vaccination in this study include combined
knowledge of vaccine and flu, good attitude towards vaccination,
being told by doctors and fellow patients who have been previ-
ously vaccinated and availability of the vaccine free of charge.
Advice from doctors about the importance of vaccination has
strongly influenced decision to get vaccinated as 97.6% of those
who were previously vaccinated were encouraged to do so by their
doctors. Therefore health care provider’s recommendation is a
cost-effective immunization implementation strategy and a strong
source of information to educate the patients regarding the bene-
fits of influenza vaccination. Vaccination promotion strategies
need to focus on encouraging health-care providers to discuss vac-
cination with their high risk clients and in providing them withaccurate and unbiased information about the risks of influenza
infection and the benefits of vaccination [40,41].
Health system processes and continuous quality improvement
can support the provider and patient in this and other effective
implementation strategies [42]. Although data collection and
tracking appears essential in effective implementation strategies,
targeting at-risk groups in subspecialty clinics and during hospital-
izations can greatly simplify this process and translate into signif-
icant cost savings and the prevention of disease.
Other strategies to improve vaccination that can be employed
include client reminder and recall system [43], community based
immunization programme for high risk [44], public awareness of
places where vaccines are available and easy access to influenza
vaccine at a subsidised cost [25]. Studies have also shown that
some of the other predictors of influenza vaccination include
awareness of vaccination recommendations, history of previous
vaccination, perceived susceptibility to influenza infection, and
perceived benefits of influenza vaccination [45,46].
A major strength of this study is the lack of previous similar
local studies, as this to the best of our knowledge is the first of
its kind in South Africa to investigate seasonal influenza vaccine
attitude, perception and knowledge among diabetics.
The limitations of this study include low response rate (70%),
and therefore a possibility of inclusion bias as included individuals
may differ from those not included. Also, there were some limita-
tions with respect to our study being a cross-sectional survey
observing a small snapshot of the population. The population
may not entirely be representative, being a hospital-based sample.
This may limit the generalization of the results. Also our question-
naire did not enquire about the availability of influenza vaccine in
the respective hospitals, alternative access to vaccine in private
sector and cost implications with respect to their income.
This studywas done after the influenza season in 2015 and there
is a possibility that some of the participants included in the analysis
of ‘‘ever vaccinated” were recently diagnosed with diabetes and
would not have had the opportunity to have received influenza vac-
cination previously. This might also introduce some bias into the
study. The outcome of this study was ever vaccinated, whereas vac-
cination in the previous year might have been a much more robust
outcome, less subject to recall bias and substantially less likely to be
biased by the number of years a person has had diabetes.
Therefore there is need for further studies among diabetics,
other high risk group and the general population especially in
the area of vaccine uptake, availability and ease of access. This will
help health-care providers and policy makers to make key decision
that will influence seasonal influenza vaccination and prevent
future outbreak.5. Conclusion
The uptake of seasonal vaccination among diabetics in Pretoria
is low. This is largely attributed to the poor knowledge of influenza
vaccine and its benefits. Diabetics are at high risk of developing
serious complications of influenza, hence the need to educate them
about this peculiarity. Despite the possibility of having flu even
with vaccination, diabetics are more likely to benefit if they get
vaccinated every autumn. Health care provider’s advice may be
an important predictor of previous influenza vaccination and they
should continue to educate and encourage all diabetics to get vac-
cinated for influenza at least once yearly.Conflict of interest
There is no conflict of interest to declare.
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Dear respondent, the information in this questionnaire is for
education and research purpose only and responses will be treated
with all confidentiality. Please answer sincerely by ticking where
appropriate or giving information as the case may be. Thank you.
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